I. Samina

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Martin H. Koldijk, G. Weverling, M. Havenga, 2007, Vaccine.

High titer West Nile IVIG from selected donors for treatment of West Nile virus infection

D. B. Nathan, A. Porgador, Orly Yahalom, 2008 .

Homologous and heterologous antibody response of cattle and sheep after vaccination with foot and mouth disease and influenza viruses.

Z. Zakay‐Rones, B. Peleg, I. Samina, 1998, Vaccine.

An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application.

M. Malkinson, Y. Khinich, I. Samina, 2005, Vaccine.

Differences in protection between heavy and light breeds of chickens following vaccination with Newcastle disease vaccines-a survey of data, 1971 to 1990.

B. Peleg, J. Brenner, I. Samina, 1992, Avian pathology : journal of the W.V.P.A.

Enhanced antibody response in cattle against Leptospira hardjo by intradermal vaccination.

A. Cohen, B. Peleg, J. Brenner, 1997, Vaccine.

Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

A. Porgador, D. Ben-Nathan, Orly Gershoni-Yahalom, 2009, BMC infectious diseases.

Human rabies in Israel.

C. Rupprecht, D. David, S. Perl, 1999, Emerging infectious diseases.

Immunization of chickens with live Newcastle disease vaccine adjuvanted with oil.

B. Peleg, J. Brenner, I. Samina, 1993, Vaccine.

Immunohistochemical Detection of Peste Des Petits Ruminants Viral Antigen in Formalin-Fixed, Paraffin-Embedded Tissues from Cases of Naturally Occurring Infection

Y. Stram, S. Perl, Z. Trainin, 1999, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

High titer human immunoglobulin as a specific therapy against West Nile virus encephalitis

D. B. Nathan, N. Orr, I. Samina, 2010, Human vaccines.

Host factors affecting the homologous and heterologous immune response of cattle to FMDV: genetic background, age, virus strains and route of administration.

Z. Zakay‐Rones, J. Weller, B. Peleg, 1998, Vaccine.